Comprehensive Strategies in Cancer Immunotherapy
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 175
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer immunotherapy has evolved significantly over the past century, beginning with early theories and experimental treatments, and progressing to the modern era, which is marked by groundbreaking innovations like immune checkpoint inhibitors, CAR-T therapies, TIL therapy, and cancer vaccines. These advancements have fundamentally shifted the paradigm of cancer patient management. Today, immunotherapy stands at the forefront of cancer treatment, ushering in a new era that offers renewed hope to patients.
Despite these recent breakthroughs, cancer continues to pose a major global challenge. It is projected that by 2025, there will be approximately 26 million new cancer cases worldwide, along with 17 million cancer-related deaths. This stark reality underscores the need for more comprehensive treatment strategies that can bridge current gaps—specifically, the discovery and development of new modalities aimed at improving clinical outcomes and providing sustainable benefits for patients.
As research delves deeper into the mechanisms governing immune cell function and their interactions with the tumor microenvironment, even more promising therapeutic options are on the horizon. The field of neoadjuvant therapy has gained significant attention, with ongoing clinical trials and innovative approaches focused on improving clinical outcomes across a range of cancer types. Additionally, there has been a renewed interest in cytokine therapy and bispecific antibodies, which show great promise when used in combination therapies to enhance anti-tumor efficacy.
Another key area of focus is the development of predictive biomarkers to forecast treatment responses. Integrating these biomarkers into clinical practice has the potential to be one of the most transformative advancements in cancer care, reshaping diagnosis, treatment selection, and the timing of interventions.
In conclusion, the future of cancer treatment and management lies in the integration of combination therapies and predictive biomarkers to enable more personalized, targeted, and effective treatments, ultimately leading to better outcomes and advancing the overall quality of healthcare.
Dr. Yee Peng Phoon
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- CAR-T
- TIL therapy
- predictive biomarker
- neoadjuvant
- cytokine therapy
- bispecific antibodies
- personalized treatment
- combination therapies
- tumor microenvironment
- immune modulation, interaction and mechanism
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
